Director / Editor: Victor Teboul, Ph.D.
Looking inside ourselves and out at the world
Independent and neutral with regard to all political and religious orientations,® aims to promote awareness of the major democratic principles on which tolerance is based.

Israel Taps SIGA Technologies' ST-246 to Combat Smallpox in Simulated Bioterror Attack

NEW YORK - SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens,  announced that it was contacted to arrange an emergency mock acquisition of its lead drug candidate and smallpox antiviral, ST-246 (Tecovirimat), by leading Israeli government health and defense officials. The mock acquisition was part of a simulated bioterror-related smallpox outbreak.

 Special Offer!
Enjoy Unlimited Access to for less than 10 cents/day.

To see the complete text of this article, you need to buy a subscription. If you already have one, please open a session.

I want to subscribe   |   Open a session

Follow us on ...
Facebook Twitter